Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whats Up IM A LONG IN AT .0001 Lets Roll IM IN AT .0016 LOVE IT BUY SELL BUY
PEACE
Good Morning The Lost Tribe Of GETA.... Im I to think that everyone is expecting GETA to drop because of DILUTION? So there are many people who are shorting GETA, and many others who are just waiting for the dilution to happen before re-entering GETA?
My Final Question, would it be possible GETA PROVES THEM ALL WRONG?
HAHAHAHEHEHE
PEACE
Squeeze play to the Moon, Excellent...Bring It i love challenges.
Catch me if you can
Peace
But can you count the sands or measure the oceans. 100,000,000,000, shares would be hard move you say. I have informed boards about this company all over Google maybe its working. My last pick I was informing investors about HESG.. which was also a .0001 Investment which climbed to 2100% or .0021 this week. But back to the question. If I had access to 100,000 investors who invested $100 or 1Million shares, how many shares would they have bought? Or you had 10,000 investors who invested $1000 or 10Million shares what would be the outcome then? Is that not the answer you were looking for? 100,000,000,000? You have me so all you need know is 9999 more investors to invest $1000 @.0001
Peace Good Luck..and help me pump this POS WTF..lol
t h i n k f i s h
NVS CHINESE TAG TEAM? FDA advisers support the drug approved for advanced breast cancer
Time: 2009-11-08 11:54 Source: Author: Click: 44 Times
FDA's oncology drug advisory committee enthusiastically supported the North China pharmaceutical company Novartis (Novartis) production of estrogen blocking drug Femara. This is the second year, FDA received these drugs, earlier, FDA approved the first one of these drugs: AstraZeneca produced by Arimidex (Anatoly yl). Novartis in the risk of estrogen-sensitive breast tumors
FDA's oncology drug advisory committee enthusiastically supported the North China pharmaceutical company Novartis (Novartis) production of estrogen blocking drug Femara. This is the second year, FDA received these drugs, earlier, FDA approved the first one of these drugs: AstraZeneca produced by Arimidex (Anatoly yl).
Novartis in the risk of estrogen-sensitive breast cancer among women has been studied on the Femara, and the gold standard control drugs and medicines - general formulations of tamoxifen were compared. Wednesday, the company provides information on the results of its research data. To participate in the debate panel, one of Indiana School of the George Sledge, said: "The clinical trial study provides a strong and compelling information on: Letrozole is very likely better than, or at least equivalent to his tamoxifen. "He strongly urged the approval of the drug.
FDA usually follow its advisory panel's recommendations.
__________________________________________________________________________
Confucius Says Genta .....
Biopharmaceutical company Genta's antisense agent Genasense (TM) to enhance breast cancer chemotherapy time :2009-11-07 13:11 Source: Author: Click: 1 & nbspGenta bio-pharmaceutical companies, scientists at the joint use of the company's anti - Yi agent Genasense (TM) product and chemotherapeutic drugs on mouse model of adriamycin-treated
To obtain a good therapeutic effect.
As the Genasense is through acting on a kind of tumor called Bcl-2 proteins play a role, so in previous studies, scientists always choose those that highly expressed
Bcl-2 protein in cancer cells to do testing. In the experiment, scientists deliberately selected a number of relatively low degree of expression of Bcl-2 protein in cancer cells to observe the Genasense in these cells to conventional chemotherapy for the degree of influence. The results showed that low expression of Bcl-2 protein in cancer cells by the Genasense pretreatment, the same right and then given doxorubicin chemotherapy had a high degree of sensitivity.
Studies have shown that, Genasense does not affect the blood concentrations of adriamycin. If you use a non-Bcl-2 protein-specific anti-sense agents to carry out pre-processing of the cancer cells will not produce this "chemotherapy sensitization" effect.
This shows that, Genasense this "chemotherapy allergenicity," both for the high or low degree of expression of Bcl-2 protein in cancer cells are valid, which has a very broad clinical application.
◆ This article from the Beijing Academy of Traditional Chinese Medicine Jinkui provided for reference only.
◆ If you have health problems need to consult a doctor, you can click on "expert advice QQ" or to conduct a detailed consultation, you can also direct dial telephone in our hospital hotline :010-84065346; we will immediately answer your questions.
◆ If you need treatment, please appointment.
Articles from http://www.767.org.cn/ | Breast Cancer Network, welcomed reproduced, reproduced well-known source please!
http://www.767.org.cn/html/ruxianzengshengruxianai/20091107/1524.html
TAI PING = PEACE in China
t h i n k w i s h
For Immediate Release: November 3, 2009
Contact: Berna Diehl
Jones Public Affairs
(202) 591-4045 Be...@JonesPA.com
Melanoma Research Foundation Leads Unprecedented
Collaboration for Melanoma Research
Patient advocacy group, research community and pharmaceutical
companies join
forces for new breakthroughs in treatment; clinical trials to begin in
2010
HILLSBOROUGH, N.J. — For more than a decade, there have been no new
therapies that have improved survival rates for patients with advanced
melanoma. Today, at the 6th International Melanoma Congress for the
Society for Melanoma Research, the Melanoma Research Foundation (MRF)
announced a novel collaboration between the research community and
pharmaceutical companies that will pool knowledge and resources to
generate new breakthroughs in treatment.
“As a community, we have hit a wall. We are fed up with melanoma
patients having so few treatment options to battle their disease. It’s
time to change course, get creative and accelerate the development of
new therapies,” said Randy Lomax, chairman of the MRF.
The MRF’s research Consortium will bring together 10 major academic
centers specializing in melanoma research, and the major
pharmaceutical companies with individual therapies that have shown
promise in melanoma. This initiative will break down traditional
barriers that hinder collaborations between companies and the research
community, and will advance the Consortium’s common goal for
developing new treatments.
“We are not aware of any other disease state that has used a model
like this to fuel new research,” said Tim Turnham, executive director
of the MRF. The Consortium’s structure and work will be groundbreaking
because of both its collaborative framework and research approach.
Research will be geared toward combining multiple investigative drugs,
rather than combining approved drugs, or an approved drug with an
investigational drug.
“Melanoma is a disease with two faces. It is curable and easy to treat
in its early stage, but advanced melanoma is resistant to the
therapies that work for other cancers,” said Keith Flaherty, M.D.,
member of the MRF’s Scientific Advisory Committee and lead physician
for the Consortium. Nearly 69,000 people are expected to be diagnosed
in the United States with the disease in 2009, resulting in an
estimated 8,650 deaths. The vast majority of melanomas are caught
early, when the cancer is easy to treat and cure. However, in its most
advanced stages few treatment options exist, and this year, one person
will die from this disease every hour.
Page 2 of 2
The Consortium provides a collaborative infrastructure that allows
researchers to partner together to conduct laboratory research and
clinical trials, and to share data and information. It also creates
open avenues of communication between researchers and partner
pharmaceutical companies. Expanded access and an increased flow of
information will allow researchers to systematically explore various
combinations of therapeutic agents—including those currently being
tested in stage II and III clinical trials only as stand-alone
therapies—that would not otherwise be possible.
“For too long we have focused on the discovery of the single drug that
will knock the table down by taking out one of four legs,” says Dr.
Flaherty. “In melanoma, we now have the tools to target enough legs to
radically change the treatment of this disease.”
For decades, the melanoma research community has focused on single-
agent approaches. Interleukin-2 (IL-2) was the last drug approved to
treat advanced melanoma, but 85% of patients derive no benefit from
this drug. The Consortium approach to research will address the
growing recognition that melanoma patients will need combination
therapies to meaningfully increase survival. Melanoma’s complex
molecular make-up means that combinations of treatments may more
effectively address the underpinnings of the disease.
“This novel approach opens up many exciting new research avenues and
combining pathways may result in a durable solution for patients that
does not exist at this point,” said Lomax.
The Consortium’s approach addresses why some trials have been
hamstrung in the past. Academic institutions often do not have the
capacity to test investigative drugs without support from
pharmaceutical companies, and pharmaceutical companies have not been
able to test combination therapies of investigational drugs without
support from research and academic institutions. “The Consortium
breaks down the barriers to collaboration, and facilitates clinical
trials that are otherwise not viable,” said Turnham.
The Consortium is coordinated by the Melanoma Research Foundation
(MRF), which is committed to accelerating medical research by bringing
together the leaders in drug development, laboratory and clinical
research for finding effective treatments and eventually a cure for
melanoma. The MRF believes this initiative will foster the development
of effective treatment options for patients with advanced melanoma.
Clinical trials are set to begin in 2010.
POST SAVING THANKS FOR READING
PEACE
Chasing you for your shares is what everyone will doing, thats why its so cold is this pool..lol Or they must know something if nobody bought today. Its okay if it goes down I just buy more, Im 51% sure it will go up and the WHALES outweight the tunas. Sorry tunas no more fish left for you..shrimps maybe.
I'll be sure to let everyone know the good news
Good Luck Happy Fishing,
thinkpeace
Thanks ryjo, I guess that sound all right...I 'll just wait here for some good news.
ryjo is that the name for lighting, I guess fishing season is over.. bu bye .17lb fishes
thinkBIGfish
287942 shares...... and then 100000..... FLY GETA , GET AWAY
Thanks RAY, you can let the Piranas out....
NO MORE .17 FISHES FOR YOU
Watch OUT Piranas are in the pool
Good Luck Finding Fish
Peace for you and Peace for me
thinkPeace
Hey just me and you. Yup me too .17 why not....its for a good cause
GO RAY YOU TELL THEM BOY....lol
Im in for more pain.... look at me I'm swimming
Watch it rise like the tides
Peace
Genasense>Dacarbazine thats the bottom line...
I think all those who sold Got Punkd by Ray, and you all fell for his master plan. He is probably on the microphone telling everyone they falsely elevated results because the blood specimen was handled roughly,he forgot they were in his golf bag one Sunday. But they retested them and Genasense is still better than Dacarbazine. They are all going to the roof to go swimming naked in the pool when the conference is all done. Thats what I heard from Gary, he is there right now holding the cue cards for Ray.
18 Nov 2015 Genta at Lazard Capital Hlthcr Conf
I like those kind of numbers .0031 but .0001 even better... those are my favorite kind of fishes. Its a good day hopefully it will get even better for all of us, it has for me. One of my little at .0001 fish's is up 1600%
Hows the water today, I don't see GETA floating belly up yet... so that must be a good sign. Maybe GETA is just waiting for the tides, if the Dollar Index starts to rise toward 80 make sure we have some lifeguards on duty. If plans to go towards 70 you will see the surf coming in.
DECEMBER BACK LOOK 2008
DOLLAR INDEX = 80.08
12/18/08 o/H*/l/c = 78.58 / 80.08* / 77.68 / 79.46/ +0.56
S&P 500 INDEX = 911.02
12/18/08 o/H*/l/c = 905.98 / 911.02*/ 877.44 / 885.28 /-19.14
Peace
If GETA shares prices are not falling from all this bad news , it is certainly going up after they scare all the smart investors out. I don't think there are to many smart ones left...
NO FISHING HERE
t h i n k f i s h i n g
Thanks.. But I would not tell to many people that. We don't know how they will react.... Im starting to love GETA more and more each passing day..I wonder how much more I will love GETA Today.
Anything Happening In The GETA News Pool?
Peace
REVERSE BOUNCE PLAY>? IS THERE SUCH A THING..
THE ONLY AGENDA THAT MATTERS IS $$$$$$$$$$$$
FDA will retire a bad drug Dacarbazine, replace it with Genasense slightly better bad drug for the next 25 -30 years .
Agenda will prove (Dacarbazine < Genasense) , then become the new baseline to test other non-working bad drugs.
(AGENDA)
Purpose
This study is being performed to prospectively
determine whether dacarbazine plus Genasense is significantly better than dacarbazine plusplacebo in chemotherapy naive patients with advanced melanoma and low baseline LDH
(GM301)
Purpose
LDH less than or equal to 0.8 times the upper limit of normal).LDH is a biomarker strongly associated with improved outcomes in a recent trial of dacarbazine plus Genasense.
If you had 500 Million for the FDA and a few Vitamin-C Pills, you too can have your own Agenda
LDH CHEAT SHEET - HOW TO PASS A FDA TRIAL
How the Test is Performed
The healthcare provider draws blood from a vein or from a heel,
finger, toe or earlobe. The laboratory then quickly spins
(centrifuges) the blood to separate the serum (liquid portion) from
the cells. The LDH test is done on the serum.
How to Prepare for the Test
Your healthcare provider may ask you to stop taking drugs that may
affect the test. Drugs that can increase LDH measurements include
alcohol, anesthetics, aspirin, clofibrate, fluorides, mithramycin,
narcotics, and procainamide. Ascorbic acid (vitamin C) can lower
levels of LDH.
Normal Results
Normal values may vary depending on your age, sex, and the specific
method used in the laboratory. A typical range is 105-333 IU/L
(international units per liter). The total LDH is often further
separated into five components (called isoenzymes) -- LDH-1, LDH-2,
LDH-3, LDH-4, and LDH-5 -- that are specific to certain regions of the
body and are expressed as percentages of the total.
What Abnormal Results Mean
LDH level can be elevated in many conditions, not just metastatic
melanoma. Higher-than-normal levels may also indicate:
• stroke
• heart attack
• various kinds of anemia
• low blood pressure
• liver disease (for example, hepatitis)
• muscle injury
• muscular dystrophy
• pancreatitis
Falsely elevated results can result if the blood specimen was handled
roughly, stored in extreme temperatures, or if the sample was
difficult to collect.
THE ONLY COMPETITION
THIS IS WHY THEY WOULD REPLACE IT
Cancer Chemotherapy for Melanoma: Dacarbazine
A Patient's Guide to Cancer Chemotherapy with Dacarbazine
From Timothy DiChiara, Ph.D., for About.com
Created: May 05, 2009
Other Names (United States)
DTIC-Dome
Approved
1975
Description
Dacarbazine is an "alkylating agent" that links together specific sections of DNA, which then prevents cell division and results in cell death. It is similar to the chemotherapy drug temozolimide.
Usage of Dacarbazine
Injection into a vein
Evidence that Dacarbazine is Effective
Dacarbazine is currently the only FDA-approved chemotherapy drug for metastatic stage IV melanoma. While it is the best available treatment and the standard against which new melanoma drugs are evaluated, it is unfortunately not very effective: a recent review of the research showed an average response rate of only 15.3% with no significant improvement in overall survival. Almost all responses were partial, with a median response duration of only 7 to 8 months. Dacarbazine has also been studied in combination with other drugs, as in the CVD (cisplatin, vincristine and dacarbazine) and BVLD (bleomycin, vincristine, lomustine and dacarbazine) combination regimens. The evidence so far, however, does not show an advantage over the use of dacarbazine alone.
Researcher Philip Lui, PharmD of Toronto General Hospital, concludes, “Dacarbazine generally produces poor outcomes. Adding other therapies offers minimal clinical advantages. In general, [the quality of dacarbazine studies] is poor and sample sizes are small. This . . . highlights the unmet need for effective treatment options for advanced melanoma.”
Potential Side Effects
Dacarbazine can cause a significant decrease in the number of blood cells in your bone marrow. It can also cause severe liver damage, and it has been associated with the development of other types of cancer.
The following serious side effects have occurred in a small percentage of people taking dacarbazine. If you experience any of these, seek emergency medical attention immediately:
• skin rash; itching or hives; pain at the injection site; and swelling of the face, lips or tongue signs of an allergic reaction)
• fever or chills, cough, sore throat, pain or difficulty passing urine
(signs of infection due to a decrease in the number of white blood cells)
• bruising; pinpoint red spots on the skin; black, tarry stools; and blood in the urine (signs of a decreased number of platelets)
• severe weakness, fainting spells and lightheadedness
(signs of a decreased number red blood cells)
The following less serious side effects have also been reported but don’t require immediate attention:
• loss of appetite
• fatigue
• muscle pain
• loss of hair
• nausea and vomiting
Interactions and Cautions
Do not take dacarbazine if you have had an allergic reaction (a “hypersensitivity reaction”) to it in the past. Tell your doctor if you take medicines to increase blood counts, such as filgrastim, pegfilgrastim and sargramostim.
ITS NOT A TOONICE GAME THEY PLAY, BUT ITS OKAY ITS THE FDA
On Oct 28, 8:47 am, TOONICE <toonicetoon...@gmail.com> wrote:
> GETA hit some pretty low levels today down over 10% today - currently
> around .65. IMO a great buy right now, they have a melanoma drug in
> Phase III - prior phase III just missed
> statistical significance, current limits enrollment due factors
> identified in retrospective analysis.
> The analysis showed that patients with average to low LDH (lactate
> dehydrogenase) responded much better to treatment and the new study
> with data coming out this fall only enrolled patients with average to
> low LDH.
>
> In my past experience with most biotechs, if a company is depending on
> this data to make or break them. It will be usually positive data,
> especially if you read between the lines. Their new phase III uses
> good results and data. I am sold here on GETA. I AM LONG until phase
> III, looking foward to it GETA LONGS
>
> Future events coming for this company:
>
> They will participate in the Melanoma conference on Nov. 12th, not too
> far away (DO I SMELL A RALLY?):http://www.chemotherapyfoundationsymposium.org/programs.html
Mr_Lotto3000 would you mind if I added †hinkfish's_Quikpicks
CATCH THESE fish's if you can
HESG OPGX FMNJ MGLG RMTD EVFL AGEL PHMB ARIO UVSE ZCNW
OVER 50% of these fish's will be WHALES
Peace
I research what is clear and what is unclear to get-answers to my Questions. Some of my knowledge or facts could be incorrect thats why I ask for your thoughts. I'm like a fish without water, but my desire to swim still remains the same.
I'll holding my shares until I can make profit, Im not a pro-golfer who can could afford to lose a few balls. So Im not taking a lost on my balls for no one, no matter how worthless they will become. I know someday they might just be priceless or worthless. ... Regardless I will sell them for value that I know they will become.
I don't know how play golf, but I'm learning how fish. I'm trying to catch all the little Genta fish's because in the hopes of catching more than one. I'll try casting out my poles with 299lb. lines, even if found that school of GETA fish' ............... what are the odds I would be lucky enough to catch some.
Dilution will be like the thief in the night, I would not want to lose all my little fish's. But it could be worst if I did not sell. I would be stuck with a bag full of fish's that would rot and smell. I'd have to change my name to stinkfish then swim away with fin behind my tail.
I'll just have to try different tactics to find that right bait. To catch all those little fish you guys hate. Maybe a 250lb. line would be better or maybe not. I'll just figure out which is better a pole or a rock. I'm at Peace catch whatever Heaven sends me, fish or not.
I have the desire is to become a Wise Whale. Strong enough to sink any ship that may cross my path. Humble enough to allow anyone in need of a ride. Ruled by My Spirit which is Undaunted by adversity and Unsurpassed, My Will a Master of the Oceans and The Prince of the Tides.....
Peace
t h i n k f i s h
NO EXTENDED PLAY :( I've never tried using it
THAT SUCKS
I didn't say it was not going in the sub pennies... it might do that today. lol
EXTENDED PLAY
?eace
GETA LOOK AT THE HIDDEN AGENDA...FDA IS IN THE BAG
Have you ever read the Agenda Trial?
I've been data mining and let me show you what I found interesting.
All GETA has to do to get FDA Approval is to prove its is better then
this 35 year old drug.....Dacarbazine
It has already done that, hands down. GETA will replace Dacarbazine,
for the next 25 -30 years. Bottom line all Agenda has to do is **
( determine whether dacarbazine plus Genasense is significantly
better than dacarbazine plus) PERIOD
Read and compare the purpose of these trials Trial of Dacarbazine With
or Without Genasense in Advanced Melanoma
(AGENDA)
Purpose
This study is being performed to prospectively**( determine whether
dacarbazine plus Genasense is significantly better than dacarbazine
plus)**placebo in chemotherapy-naive patients with advanced melanoma
and low baseline LDH
(GM301)
Purpose
**(LDH less than or equal to 0.8 times the upper limit of normal).LDH
is a biomarker strongly associated with improved outcomes in a recent
trial of dacarbazine plus Genasense.
I believe Genasense will preform the best when its efficacy
parameters have been met LDH [⩽1.1×upper limit of normal (ULN)], The drug was used to early so it did not show a significance in and was used to
late to be effective last trial.
Bottom line all Agenda has to do is **( determine whether dacarbazine
plus Genasense is significantly better than dacarbazine plus) PERIOD
_____________________________________
AGENDA
**(LDH less than or equal to 0.8 times the upper limit of normal)
COMPARE VS <.8 significant?
<1.1
GM301
**(All efficacy parameters significantly favoured dacarbazine–
oblimersen in patients with normal baseline **LDH [⩽1.1×upper limit of
normal (ULN)]**
Timing is everything,
*****Dacarbazine generally produces poor outcomes. Adding other
therapies offers minimal clinical advantages. In general, [the
quality of dacarbazine studies] is poor and sample sizes are small.
This . . . highlights the unmet need for effective treatment options for
advanced melanoma.”*****
Cancer Chemotherapy for Melanoma: Dacarbazine
DTIC-Dome
FDA Approved****
1975****
Description
Dacarbazine is an "alkylating agent" that links together specific
sections of DNA, which then prevents cell division and results in
cell
death. It is similar to the chemotherapy drug temozolimide.
Usage of Dacarbazine
Injection into a vein
Evidence that Dacarbazine is Effective ?NOT
Dacarbazine is currently the only FDA-approved chemotherapy drug for
metastatic stage IV melanoma. While it is the best available
treatment and the standard against which new melanoma drugs are evaluated, it is unfortunately not very effective: a recent review of the research
showed an average response rate of only 15.3% with no significant
improvement in overall survival. Almost all responses were partial,
with a median response duration of only 7 to 8 months. Dacarbazine has
also been studied in combination with other drugs, as in the CVD
(cisplatin, vincristine and dacarbazine) and BVLD (bleomycin,
vincristine, lomustine and dacarbazine) combination regimens. The
evidence so far, however, does not show an advantage over the use of
dacarbazine alone.
Researcher Philip Lui, PharmD of Toronto General Hospital, concludes,
“
Hey what if Genasense didn't work ......... that well, its better
than the 35 year old standard. Its time for the standard to retire.
Peace ... GETA conspiracy theory or plausible ?
thinkfish
Cashing in? what note holders are you talking about? Are they the same ones that have to wait cashing out until the pps is above 50 for for the required amount of time....I was wondering that too, they could of cash out before the crash...and they didn't.
Thanks for that link.... it will probably help me out another day..lol
?eace
MM's are stuck LOL everyone knows what they want to do.... only one way go if it not up.... whatever sideward spiral ....still going down to where GETA wants to go.
Peace
Thats what we heard before...Now we get to see the Fax ...Great
Black Monday ....WHAT DAY Will GETA BE GREEN?
?eace
REALLY WHAT ELSE DOES GETA NEED EXCEPT
RAY, A FAX MACHINE, A MICROPHONE.....AND A WALLET BIG ENOUGH FOR ALL OUR MONEY..
NOT SO FUNNY
PEACE
It's 11:38PM, I'll see all of you in a few..
God Luck To Us All
I might just be selling ... who knows, sweet dreams.
I can't go to sleep .......thats how I screwed my self last time, I over slept and lost the GETA worm...I hope it will be a good day for catching worms, either or it will still be a good day. Because Im at peace with the worst and will be bless for the best.
Countfish....Good Luck Everyone,
Yes ShakabudakaMan this is a GETA Board ....DOH
I cant believe I sacrificed a post to you....lol
Peace....well what smart thing did you want to say today?
This DD is dedicated to you
WTF? POT CURE FOR CANCER? http://www.medicalnewstoday.com/articles/123098.php
Not familiar with clinical research about marijuana's potential anti-cancer properties?You're not alone.
Pot Shows Promise as Cancer Cure
Clinical research touted by the journal of the American Association for Cancer Research that shows marijuana's components can inhibit the growth of cancerous brain tumors is the latest in a long line of studies demonstrating the drug's potential as an anti-cancer agent. Not familiar with it? You're not alone.
Despite the value of these studies, both in terms of the treatment of life-threatening illnesses and as items of news – the latest being that performed by researchers at Madrid's Complutense University that found cannabis restricts the blood supply to glioblastoma multiforme tumors, an aggressive brain tumor that kills some 7,000 people in the United States per year – U.S. media coverage of them has been almost non-existent.
Why the blackout? For starters, all of these medical cannabis studies were conducted overseas. Secondly, not one of them has been acknowledged by the U.S. government.
This wasn't always the case. In fact, the first experiment documenting pot's anti-tumor effects took place in 1974 at the Medical College of Virginia at the behest of the U.S. government. The results of that study, reported in an Aug. 18, 1974, Washington Post newspaper feature, were that marijuana's psychoactive component, THC, "slowed the growth of lung cancers, breast cancers and a virus-induced leukemia in laboratory mice, and prolonged their lives by as much as 36 percent."
Despite these favorable preliminary findings, U.S. government officials banished the study, and refused to fund any follow-up research until conducting a similar – though secret – clinical trial in the mid-1990s. That study, conducted by the U.S. National Toxicology Program to the tune of $2 million concluded that mice and rats administered high doses of THC over long periods had greater protection against malignant tumors than untreated controls.
However, rather than publicize their findings, government researchers shelved the results, which only became public after a draft copy of its findings were leaked in 1997 to a medical journal which in turn forwarded the story to the national media.
However, in the eight years since the completion of the National Toxicology trial, the U.S. government has yet to fund a single additional study examining the drug's potential anti-cancer properties. Is this a case of federal bureaucrats putting politics over the health and safety of patients? You be the judge.
Fortunately, scientists overseas have generously picked up where U.S. researchers so abruptly left off. In 1998, a research team at Complutense's Department of Biochemistry and Molecular Biology discovered that THC can selectively induce program cell death in brain tumor cells without negatively impacting the surrounding healthy cells. Then in 2000, they reported in the journal Nature Medicine that injections of synthetic THC eradicated malignant gliomas (brain tumors) in one-third of treated rats, and prolonged life in another third by six weeks.
Last year, researchers at the University of Milan in Naples, Italy, reported in the Journal of Pharmacology and Experimental Therapeutics that non-psychoactive compounds in marijuana inhibited the growth of glioma cells in a dose dependent manner, and selectively targeted and killed malignant cells through a process known as apoptosis.
And finally, this month, researchers reported that marijuana's constituents inhibited the spread of brain cancer in human tumor biopsies from patients who had failed standard cancer therapies.
Nevertheless, federal officials in this country have refused to express any interest in funding – or even acknowledging – this clinical research. By doing so, they are doing a disservice not only to the scientific process, but also to the health and well being of America's citizenry. Paul Armentano is the senior policy analyst for the NORML Foundation in Washington, DC.
http://www.alternet.org/drugreporter/20008/WTF
THANKS...KEEP IT COMING
H4 = [1.1*(H-L)/2]+C
H3 = [1.1*(H-L)/4]+C
H2 = [1.1*(H-L)/6]+C
H1 = [1.1*(H-L)/12]+C
L1 = C-[1.1*(H-L)/12]
L2 = C-[1.1*(H-L)/6]
L3 = C-[1.1*(H-L)/4]
L4 = C-[1.1*(H-L)/2]
GETA NEEDS TO DO THIS OR THEY ARE OUT
Bristol-Myers Squibb will be in, how are their finances?
FDA LOVES Bristol-Myers Squibb
one-year survival rate of 47% to 51% How can you not?
ipilimumab (MDX-010, MDX-101, or BMS-734016) - Ipilimumab is an antibody that activates the body's immune system to fight melanoma by inhibiting the CTLA-4 molecule. Three previous phase II clinical trials have shown that treatment with ipilimumab results in a one-year survival rate of 47% to 51% for people with stage III or IV melanoma, which is almost double the average. The current trial is comparing ipilimumab to a dummy treatment (placebo) in patients with stage III melanoma who have already undergone surgery. Made by Medarex and Bristol-Myers Squibb. Find out more about the EORTC 18071 trial for ipilimumab.
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
This study is currently recruiting participants.
Verified by Bristol-Myers Squibb, July 2009
First Received: March 7, 2008 Last Updated: November 4, 2009 History of Changes
Sponsor: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00636168
Purpose
The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma
Condition Intervention Phase
High Risk Stage III Melanoma
Drug: ipilimumab
Drug: Placebo
Phase III
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Just Facts Peace
I will have 24800 shares tomorrow for $5 buck, youy how muck you would have if you spend $10 yup almost 50000 shares
On the serious note do you know how to manipulate LDH DATA?
I DO...
Drugs that can increase LDH measurements include alcohol, anesthetics, aspirin, clofibrate, fluorides, mithramycin, narcotics, and procainamide. Ascorbic acid (vitamin C) can lower levels of LDH.
SO DOES GETA, FDA, & SEC
I hope they are Honest or we are all screwed
Guide to the LDH Test for Melanoma
What You Need to Know About LDH for the Diagnosis of Melanoma Metastases
From Timothy DiChiara, Ph.D., for About.com
Created: May 20, 2009
About.com Health's Disease and Condition content is reviewed by the Medical Review Board
http://skincancer.about.com/od/diagnosis/a/LDH.htm
id your doctor order an LDH test? This introduction will explain what the test measures, what the results mean, and its effectiveness in detecting metastasis in patients with melanoma skin cancer.
Definition
LDH is a blood test that measures the amount of an enzyme in the blood called "lactate dehydrogenase" (LDH). Chemically, LDH is involved in the conversion of pyruvate and lactate in the body. For example, the accumulation of lactate is the cause of sore muscles after a heavy workout.
Other Names
LD, lactate dehydrogenase, lactic dehydrogenase, total LDH, LDH isoenzymes
Why the Test Is Performed
In general, the LDH level is measured in order to check for tissue damage, especially to the heart, liver, kidney, skeletal muscle, brain, and lungs, which elevates the normally low LDH level in the blood. For patients with melanoma, it is used to determine if the cancer has metastasized (spread) to organs beyond the skin or lymph nodes, usually to the liver or lungs. Although LDH is not specific for melanoma, it may be useful at diagnosis or to monitor post-surgery (adjuvant) treatment. The staging system for melanoma uses the LDH level to subdivide patients with stage IV disease.
How the Test is Performed
The healthcare provider draws blood from a vein or from a heel, finger, toe or earlobe. The laboratory then quickly spins (centrifuges) the blood to separate the serum (liquid portion) from the cells. The LDH test is done on the serum.
How to Prepare for the Test
Your healthcare provider may ask you to stop taking drugs that may affect the test. Drugs that can increase LDH measurements include alcohol, anesthetics, aspirin, clofibrate, fluorides, mithramycin, narcotics, and procainamide. Ascorbic acid (vitamin C) can lower levels of LDH.
Normal Results
Normal values may vary depending on your age, sex, and the specific method used in the laboratory. A typical range is 105-333 IU/L (international units per liter). The total LDH is often further separated into five components (called isoenzymes) -- LDH-1, LDH-2, LDH-3, LDH-4, and LDH-5 -- that are specific to certain regions of the body and are expressed as percentages of the total.
What Abnormal Results Mean
LDH level can be elevated in many conditions, not just metastatic melanoma. Higher-than-normal levels may also indicate:
• stroke
• heart attack
• various kinds of anemia
• low blood pressure
• liver disease (for example, hepatitis)
• muscle injury
• muscular dystrophy
• pancreatitis
Falsely elevated results can result if the blood specimen was handled roughly, stored in extreme temperatures, or if the sample was difficult to collect.
Research
Multiple prior studies have shown that an elevated LDH level can predict survival in patients with advanced melanoma. For this reason, it was included in the 2002 staging system for melanoma. Patients with stage IV melanoma and elevated LDH have the worst prognosis of any stage of the disease.
Beyond categorizing patients with stage IV disease, the LDH test is actually not very specific or sensitive for detecting melanoma metastases in the first place. For example, a recent study followed patients with melanoma for 2.5 years after surgery. The results showed that LDH level was not a good marker for "in transit metastasis" (stage IIIC melanoma that has spread beyond the skin lesion but not to the lymph nodes) or spread to local lymph nodes. Furthermore, it only accurately identified distant metastasis in a minority of patients. A test for another blood protein called S-100B is emerging as a better marker than LDH and so may be incorporated into future staging systems.
Conclusion
If your doctor has ordered a test for LDH, or even if the results come back and the level is high, there is no reason to panic. LDH is not a reliable marker of metastatic melanoma, so a high level is only a "head's up" for the doctor to investigate the situation further with a CT/PET/MRI scan or sentinel lymph node biopsy. If you have any questions or concerns about interpreting your LDH test results, be sure to discuss them with your doctor.
Sources:
Egberts F, Hitschler WN, Weichenthal M, Hauschild A. "Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse" Melanoma Research 2008. 26 February 2009.
Nervous Peaces
I would like to write you all back, but I saving my last 12.95 to buy GETA tomorrow. Im buying 24,800 shares of GETA with my $12.95
Lets see thats...
$.4.96 to GETA @.0002 24800
-7.99 to Etard
$5 GETA = $25,000. @ $1
Then I can afford to go to the Pacquiao Vs Mayweather Fight
& Ihub subsription.
If you know a better price than .0002
just whisper it to me?
I'd gladly pay you Tuesday for a Subscription today"
All I would need is 2 cents from all of you.
Finding GETAGO
Me and Gary & Miss Dixon ......
.....the other two shareholders.
http://upload.wikimedia.org/wikipedia/commons/4/4a/Popeye-meets-ali-baba.jpg
Which Way Did GETAGO?..... fill in your 2 cent pledge
H = Days High / 2000
L = Days Low / .0002
C = Days Close / .0200
Your Lucky only 11 more to read
Peace
Etrade can buy and sell open a account and transfer your shares there, if you want to buy and sell, MGLG.
Whats the plan if you can't sell?
You guys just come back here everyday to cuss at Karen ......lol
Check out this these .0001- .0004 stocks,
$100 in HTDS @.0001 in Dec.08
You could of been $20000 less poor a few days ago.
HESG ...IM UP 300%
Bid .0003/ .0004 Ask
FNMJ .....
0001 Bid / .0002 Ask....0001 sometimes
RMTD....
0000 Bid / LOL .0001 Ask... sleeping giant
OPGX.....
0002 Bid / .0004 ask
$1000 get you a 1 Million @ .10...
Or 10 Million @ $1.00
PEACE
Tell Karen she smells like gAASSS
Everyday was a Black Day for GETA one time or another...lol thanks
Hi folks,
Its your lucky day I only have 13 post left today, so I'll try to make them good.
First of all I think we will be chasing GETA Monday, down or up but we will be chasing.
Restructure? Would GETA have to if the pps raised? Like to $1.20-$3.85?
Would it still be needed? Of course at .0002 it would but honestly try it for once.
Thanks
The Top 5 Most Promising Upcoming Drugs for Melanoma
Treatment of advanced (stage III and IV) melanoma is in desperate need of some good news. Although the incidence of melanoma is increasing by a whopping 3 to 5% per year in the United States, current therapies don't significantly increase survival in most patients and no new first-line medicines have been approved in over 10 years.
Clinical trials are the best hope for a long-lasting reduction or elimination of metastatic melanoma (called a "durable response" or "complete response" by doctors). The US National Institutes of Health lists 27 late-stage (phase III) clinical trials currently recruiting patients with melanoma. Many of the trials are testing new combinations of existing drugs, new ways to administer them, or new surgical procedures, but some are investigating brand new drugs. The most promising are the following:
Allovectin-7 - This novel gene therapy is injected directly into the tumors of patients with stage III or IV disease, which then alerts the body's own immune system to attack the tumor. Earlier trials of Allovectin alone showed that tumors in 4% to 9% of patients responded to the therapy. The new trial is comparing Allovectin-7 to the standard chemotherapy treatment, either dacarbazine or temzolomide. Made by Vical. Find out if you may qualify for the AIMM trial of Allovectin-7.
oblimersen (Genasense) - Genasense is a unique inhibitor of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced cell death (called "apoptosis"). So by reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Previous studies demonstrated that Genasense combined with the chemotherapy drug dacarbazine tripled response rate and significantly increased overall survival compared to dacarbazine alone. Made by Genta. Find out more about the AGENDA trial of oblimersen.
MVax - MVax is a melanoma vaccine prepared from the patient's own cancer cells. Several studies have shown that MVax followed by interleukin-2 can lead to a complete response in up to 13% of patients, double that of interleukin-2 alone. MVax is also effective in patients with stage III melanoma when given post-surgery: it doubled the 5-year survival rate compared to surgery alone. Made by AVAX Technologies. Find out more about the MVALDI trial for MVax.
ipilimumab (MDX-010, MDX-101, or BMS-734016) - Ipilimumab is an antibody that activates the body's immune system to fight melanoma by inhibiting the CTLA-4 molecule. Three previous phase II clinical trials have shown that treatment with ipilimumab results in a one-year survival rate of 47% to 51% for people with stage III or IV melanoma, which is almost double the average. The current trial is comparing ipilimumab to a dummy treatment (placebo) in patients with stage III melanoma who have already undergone surgery. Made by Medarex and Bristol-Myers Squibb. Find out more about the EORTC 18071 trial for ipilimumab.
OncoVEXGM-CSF - OncoVEXGM-CSF is a vaccine that works by spreading within tumors and causing the death of cancer cells while stimulating the immune system to destroy metastatic tumors. Previous results from 50 patients with inoperable stage IIIc/IV melanoma demonstrated that 28% of patients responded, including 12% with a complete response. The new trial is enrolling patients with previously treated but inoperable stage IIIb, IIIc or IV melanoma and is designed to compare OncoVEXGM-CSF to a naturally-occurring substance in the body called a "granulocyte monocyte colony stimulating factor" (GM-CSF), which increases white blood cells. Made by BioVex. Find out more about the trial for OncoVEXGM-CSF.
IF THIS AGENDA FAILS, LOOK ON THE BRIGHT SIDE GETA CAN MAKE ANOTHER COCKTAIL.
BLOODY GETA ON THE ROCKS , WITH A MDX CHASER
....PLEASE
Estimated Study Completion Date: September 2014
ipilimumab (MDX-010, MDX-101, or BMS-734016
one-year survival rate of (47% to 51%) for people with stage III or IV melanoma,
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
This study is currently recruiting participants.
Verified by Bristol-Myers Squibb, July 2009
First Received: March 7, 2008 Last Updated: November 4, 2009 History of
Changes
Sponsor: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00636168
Purpose
The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma
Condition Intervention Phase
High Risk Stage III Melanoma
Drug: ipilimumab
Drug: Placebo
Phase III
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Resource links provided by NLM:
MedlinePlus related topics: Melanoma
Drug Information available for: Ipilimumab
U.S. FDA Resources
Further study details as provided by Bristol-Myers Squibb:
Primary Outcome Measures:
To determine whether post-operative adjuvant therapy with ipilimumab improves recurrence-free survival (RFS) as compared to placebo [ Time Frame: Upon occurrence ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
To determine whether post-operative adjuvant therapy with ipilimumab improves overall survival (OS) as compared to placebo [ Time Frame: Upon occurrence ] [ Designated as safety issue: No ]
To determine whether post-operative adjuvant therapy with ipilimumab improves distant metastases-free survival (DMFS) as compared to placebo [ Time Frame: Upon occurrence ] [ Designated as safety issue: No ]
To compare adverse event profiles between patients receiving ipilimumab versus
patients receiving placebo [ Time Frame: Upon occurrence ] [ Designated as safety issue: No ]
To compare quality of life and quality-of-life-adjusted survival between the two treatment groups (ipilimumab versus placebo) [ Time Frame: Upon occurrence ] [ Designated as safety issue: No ]
Estimated Enrollment: 950
Study Start Date: June 2008
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date October 2012 (Final data collection date for primary outcome measure)
PEACE
GOOD LUCK WE ARE GOING TO NEED IT
Miss Dixon, I agree with GETA's strategic PR plan..Why is it a Black Thursday, after Monday I thought all/most of the days will be green. Share your data with us not with those yahoo's.
Good luck with that report, was that your excuse for data mining tonight. Don't forget to take your kids fishing.
Peace My Sister
† h i n k f i s h
The Magic Beans Of Genta
Fe Fi Fo Fum, Im not selling them to anyone.
"A fool sees not the same tree that a wise man sees"
WILLIAM BLAKE
Wise Man or Fool you will see, won't we.....
Peace
IYHO what is a incredibly LOW PPS....... REALISTICALLY
PEACE
“You Can’t Start a Fire Without a Spark!!”
As Dr. Casey Culberson Said:
"The BEST melanoma patient is an ACTIVE PARTICIPANT in his or her treatment
(not a PASSIVE RECIPIENT)"
http://melanomamissionary.blogspot.com/
TUESDAY, NOVEMBER 10, 2009
E Petition For BMS's Compassionate Investigational Drug Access.Melanoma..Jim Breitfeller
E Petition For BMS's Compassionate Investigational Drug Access
It is time to rally the Melanoma Patients and take back the Clinical Trials.
Bristol-Meyer Squibb halted the compassionate Drugs stating a drug shortage. There is evidence out there that the shorage was over months ago. They left the Melanoma Patients falling through the cracks of the Health Care System. We need change NOW!!!!!
Please sign the E Petition at Melanoma Missionary
Take Care,
Jimmy B
DELCATH INFO
Call for Patients with Unresectable Liver Metastases Due to Melanoma
Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma
Delcath is actively enrolling patients in a Phase III clinical trial testing its proprietary drug delivery system, known as Percutaneous Hepatic Perfusion (“PHP”), with melphalan for the treatment of ocular and cutaneous melanoma metastatic to the liver.
Orphan drug designation, when granted by the FDA’s Office of Orphan Products Development, allows for up to seven years of market exclusivity upon FDA approval, as well as clinical study incentives, study design assistance, waivers of certain FDA user fees, and potential tax credits.
Check out the link, useful info.
PEACE For Jimmy B "The BEST melanoma patient"
SELL, SELL, SELL If I was a day trader that would be the thing to do. Since Im not and my Etard account has been put on a 90 day restriction to trade until my trades clear. I have to plan my trades three days in advance, also Im not allowed to trade in and out of a stock more than 4 times in a week. These are the M&M's tools that they use against us everyday investors, and they are able to manipulate and calculate mine and others trades. So folks if you only had four moves to make a week, you better make them GOOD. I know my four how about yours?
Check Mate
PEACE
Could be true, but what if....
Ray has to watch what he says these days, due the fact the SEC must approve of every word he has to say?
We could hear on the CC:
1) Reduce expenses getting GENTA from end January to to end of March, other wise the future looks GLOOMY
2) GENTA is looking into different avenues of financing for 2010, if not could spell DOOM for the company.
3) Not a so great earnings update , but better than last year..lol
4) More updates on Agenda will be announced at 5pm
Monday Nov.16, 5PM
1)OS 50% median will been known Jan 15 or sooner based on death rate so far (62% still alive as of October 29 PR). Futility analysis updated in Nov 4 PR to continue to clinical data.
2)Quantitative data presented will show the OS end-point in the bag.
3)New future collaborated partnerships in the works to battle melanoma cancer.
5)Update of current and future products in pipeline
4)Further Agenda numbers will be announced in Berlin, Nov,19
What If?
PEACE
Time Knows The Answer..
As I see it, M&M's make a cool million for every 5% gain. Monday Nov.16, is one those days they live for. Since these type of days are very rare, at least for most companies. GETA is in exception... lol, Monday is the type of day these M&M's will gain a minimum 50x the usual 5%-10% daily gains. As you all experienced from the past they will manipulate the market best they can. All we can really do is be ready for what ever Heaven throws at us. M&M's do believe they are gods, which we must see through the manipulation and prove them wrong. They love to melt money from our wallets and they enjoy leaving that bitter taste in your mouth.
"Unhappy the general who comes on the field of battle with a system"
NAPOLEON I
Peace
Good Luck to those who keep the FAITH, Whats the worst that can happen vs the best... You weight out.
"Be Faithful when others are Faithless" M®
PEACE
t h i n k f i s h